Companies › 4TEEN4 Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AK1967 (Invobenitug also known as Procizumab) DPP3 inhibition using humanized monoclonal antibody | DPP3 | Phase 1 | Shock, Cardiogenic | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06832722 | AK1967 (Invobenitug also known as Procizumab) | Phase 1 | Shock, Cardiogenic | Other | Dec 2026 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.